Compare United Microelectronics Corp (UMC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Microelectronics Corp vs State Street SPDR S&P Biotech ETF — how do they compare? United Microelectronics Corp trades at $22.96 (market cap $58.02B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: United Microelectronics Corp is far larger — about 5.7× State Street SPDR S&P Biotech ETF's market cap, and United Microelectronics Corp pays a 1.76% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold United Microelectronics Corp for 42 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UMC | XBI | |
|---|---|---|
Market Cap | $58.02B | $10.11B |
Volume | 11,897,809 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $28.02 | $169.55 |
52-Week Low | $7.02 | $104.99 |
Typical Hold Time | 42 Days | 38 Days |
Enterprise Value | $55.10B | — |
Dividend Yield | 1.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UMC trades at $22.82, down 2.1% today but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals despite mixed moving averages, while fundamentals reveal robust profitability with 32.75% net income margin and improving cash flow trends. Recent news highlights analyst upgrades and strong AI-driven growth prospects.
Outlook remains positive with projected revenue growth to $250.7B in 2026 and intrinsic value estimates around $29 suggesting upside potential. Key risks include semiconductor cycle volatility and competitive pressures from larger foundries. Analyst consensus leans Hold but recent Strong Buy upgrades indicate growing optimism.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
